Andrew Weber is a Research Director with the ATOM Consortium, a public-private consortium developing accelerated workflows for the discovery of small molecule cancer therapeutics. His current research focus areas are on generative networks for optimization of chemical structure in high performance compute workflows, predictive pharmacokinetics, and drug induced liver injury. Andrew has over 10 years of drug discovery and development experience at GlaxoSmithKline, deploying computational modelling techniques applied to pharmacokinetics (including physiologically based pharmacokinetics), pharmacodynamics, transnational medicine, systems toxicology, route of delivery, and manufacturing throughput and cost of goods. Andrew has a M.S. in Chemical Engineering from Villanova University and a B.S. in Chemical Engineering from Bucknell University.